National Consultation on Nepal’s Graduation from the LDC Category, Implementation of IPoA and SDGs Held

National Consultation on Nepal’s Graduation from the LDC Category, Implementation of IPoA and SDGs Held


Details

Decision on WTO LDC TRIPS Pharmaceutical Waiver Extension: Only 17 Years!

Published Date: January 21, 2022, at 7:14 am

Our year-long advocacy for an indefinite transition period of exemption/waiver to LDCs for pharmaceutical products has now ended with the final deal reached! Please see attached, the statement released by LDC Watch critiquing the weak deal.

Yesterday 6th November, the WTO TRIPS Council adopted the decision to grant 17-year transition period of exemption/waiver to LDCs regarding pharmaceutical products. We have expressed our disappointment and critique over this weak deal which is only 3 years more compared to the existing one (which ends this year) of 14 years granted in 2001. We had been advocating for an indefinite transition period of exemption/waiver, until a country exits the LDC category, given continual gross health challenges in LDCs.

Please also see attached, the joint NGO statement released by some of the groups in the South (including LDC Watch) and North who were engaged with governments in the advocacy. The statement is covered on http://www.ip-watch.org/weblog/wp-content/uploads/2015/11/Joint-NGO-StatementFinal.pdf

The United States and the LDCs had agreed to a 17-year transition period on 29 October at a high-level meeting between US Ambassador Michael Punke and representatives of the LDC Group, Ambassador Shameem Ahsan from Bangladesh and Ambassador Christopher Onyanga Aparr from Uganda. The US had initially offered only a 10-year transition period.

Please see related articles: 

 

FileFile size
Download this file (council_recommedation_for_mailbox_and_exclusive_marketing rights.pdf)

Council recommedation_for_mailbox and exclusive marketing rights

29 kB
Download this file (Joint_NGO_Statement_final.pdf)

Joint NGO Statement

2412 kB
Download this file (ldcwatch statement on ldc trips pharmaceutical 17yr extens.pdf)

LDC Watch statement

170 kB
Download this file (statement_by_bangladesh.pdf)

Statement by Bangladesh

11 kB
Download this file (statement_by_nepal.pdf)

Statement by Nepal

26 kB

Facebook

Contact Us  

Contact LDC Watch

International Secretariat

LDC Watch

P.O.Box: 8130, 288 Gairidhara Marg, Gairidhara

Kathmandu, Nepal

Tel: +977 1 4004507, 4004985, 4004976

Fax: +977 1 4004508

E-mail: info@ldcwatch.org

Web: www.ldcwatch.org

 

 

European Co-ordination Office

115 Rue Stevin, B – 1000, Brussels, Belgium

Tel: +322 231 1659

Fax: +322 230 3780

Google Map Location: